Board Meeting Details

The meeting was held at the company's registered office in Ahmedabad. It commenced at 4:45 PM and concluded at 5:25 PM.

Key Agenda Item Approved

The Board considered and approved the unaudited financial results of the company for the quarter and half-year ended September 30, 2026, along with the Limited Review Report issued by the statutory auditors.

Financial Performance (Quarter Ended September 30, 2026)

Income Statement (₹ in Lakhs):

  • Revenue from Operations: ₹166.08
  • Other Income: ₹8.83
  • Total Income: ₹174.90
  • Total Expenses: ₹168.07
  • Purchase of Traded Goods: ₹142.32
  • Changes in Inventories of Traded Goods: (₹24.16)
  • Employee Benefits Expense: ₹4.31
  • Finance Cost: ₹1.19
  • Depreciation and Amortization: ₹4.21
  • Other Expenses: ₹40.20
  • Profit Before Tax: ₹6.83
  • Tax Expense: ₹1.88
  • Current Tax: (₹0.10)
  • Deferred Tax: ₹1.99
  • Net Profit for the Period: ₹4.95
  • Earnings Per Share (Basic & Diluted): ₹0.0020

Comparative Financial Performance

Quarterly Comparison (₹ in Lakhs):

  • Revenue declined from ₹312.74 (Q1 FY27) and ₹254.65 (Q2 FY26)
  • Net Profit declined from ₹14.31 (Q1 FY27) and ₹13.55 (Q2 FY26)

Half-Yearly Performance (₹ in Lakhs):

  • Total Income: ₹492.85 (vs. ₹583.47 in H1 FY26)
  • Net Profit: ₹19.26 (vs. ₹23.30 in H1 FY26)
  • EPS (Basic & Diluted): ₹0.0080 (vs. ₹0.0099 in H1 FY26)

Capital Structure

  • Paid-up Equity Share Capital: ₹2,413.57 lakhs (24,135,700 shares of ₹1 face value each)
  • Other Equity (Reserves & Surplus): ₹1,111.81 lakhs (unaudited)

Balance Sheet Position as at September 30, 2026 (₹ in Lakhs)

Assets:

  • Total Assets: ₹4,002.21
  • Non-Current Assets: ₹3,381.54
  • Property, Plant and Equipment: ₹32.11
  • Right of Use Assets: ₹120.33
  • Capital Work in Progress: ₹3,161.91
  • Other Non-Current Assets: ₹67.20
  • Current Assets: ₹620.67
  • Inventories: ₹29.96
  • Trade Receivables: ₹116.50
  • Cash and Cash Equivalents: ₹142.55
  • Other Current Assets: ₹331.67

Liabilities and Equity:

  • Total Equity: ₹3,525.38
  • Total Liabilities: ₹476.83
  • Non-Current Liabilities: ₹117.00 (Lease Liability)
  • Current Liabilities: ₹359.83
  • Trade Payables: ₹152.92
  • Lease Liability: ₹27.34
  • Contract Liabilities: ₹175.95
  • Other Current Liabilities: ₹3.62

Cash Flow Statement (Half-Year Ended September 30, 2026)

  • Cash Flow from Operating Activities: ₹223.36
  • Cash Flow from Investing Activities: (₹374.76)
  • Cash Flow from Financing Activities: (₹6.52)
  • Net Decrease in Cash: (₹186.20)
  • Cash at Beginning: ₹328.75
  • Cash at End: ₹142.55

Fund Utilization Disclosure

The company reported no deviation or variation in the utilization of funds raised through:

1. Public Issue (Allotment: 25.03.2022) - ₹360 lakhs

2. Preferential Issue (Allotment: 05.01.2023) - ₹520.80 lakhs

3. Preferential Issue (Allotment: 16.01.2024) - ₹1,572.48 lakhs

4. Preferential Issue (Allotment: 23.03.2026) - ₹348 lakhs

All funds were utilized according to their original objects:

  • Funding purchase of machineries and equipment: ₹275.82 lakhs
  • General Corporate Purpose: ₹59.18 lakhs
  • Issue-related Expenses: ₹25.00 lakhs
  • Preferential Issue proceeds: Fully utilized as intended

The Audit Committee reviewed and found no deviation in fund utilization.

Additional Information

  • The company operates in a single reportable segment: Pharmaceuticals Business
  • Financial results prepared in accordance with Indian Accounting Standards (Ind AS)
  • Previous period figures have been regrouped/rearranged/reclassified where necessary